Dydrogesterone in threatened abortion: pregnancy outcome
- PMID: 16293412
- DOI: 10.1016/j.jsbmb.2005.08.013
Dydrogesterone in threatened abortion: pregnancy outcome
Abstract
Objective: To determine whether therapy with dydrogesterone in threatened abortion during the first trimester of pregnancy will improve pregnancy outcome.
Design: Prospective open study.
Subjects: Pregnant women presenting to the obstetric and gynaecology clinic admitting center with vaginal bleeding before 13 weeks gestation were evaluated for entry into the study. Women were excluded if they had a history of recurrent miscarriage.
Method: Eligible subjects were randomized to receive either dydrogesterone 40 mg stat dose followed by 10 mg twice a day for one week or conservative therapy.
Results: One hundred and 54 women were recruited. There was no statistically significant differences between the two groups with regard to pre-treatment status. The continuing pregnancy success rate was significantly (p=0.037) higher in women treated with dydrogesterone (95.9%) compared with women who received conservative treatment (86.3%). The odds ratio of the success rate between dydrogesterone treatment and non-treatment was 3.773 (95% confidence interval: 1.009-14.108).
Conclusion: Corpus luteal support with dydrogesterone has been shown to reduce the incidence of pregnancy loss in threatened abortion during the first trimester in women without a history of recurrent abortion.
Similar articles
-
Dydrogesterone in threatened miscarriage: a Malaysian experience.Maturitas. 2009 Dec;65 Suppl 1:S47-50. doi: 10.1016/j.maturitas.2009.11.016. Epub 2009 Dec 14. Maturitas. 2009. PMID: 20005647 Clinical Trial.
-
Dydrogesterone support in threatened miscarriage.Maturitas. 2009 Dec;65 Suppl 1:S43-6. doi: 10.1016/j.maturitas.2009.11.013. Epub 2009 Dec 14. Maturitas. 2009. PMID: 20007011 Clinical Trial.
-
Use of oral progestogen in women with threatened miscarriage in the first trimester: a randomized double-blind controlled trial.Hum Reprod. 2021 Feb 18;36(3):587-595. doi: 10.1093/humrep/deaa327. Hum Reprod. 2021. PMID: 33331637 Clinical Trial.
-
Efficacy of progesterone on threatened miscarriage: Difference in drug types.J Obstet Gynaecol Res. 2019 Apr;45(4):794-802. doi: 10.1111/jog.13909. Epub 2019 Jan 10. J Obstet Gynaecol Res. 2019. PMID: 30632226 Review.
-
Dydrogesterone use in early pregnancy.Gynecol Endocrinol. 2016;32(2):97-106. doi: 10.3109/09513590.2015.1121982. Epub 2016 Jan 22. Gynecol Endocrinol. 2016. PMID: 26800266 Review.
Cited by
-
PERİDER-TJOD joint review on threatened abortion and guideline for its treatment.Turk J Obstet Gynecol. 2025 Mar 10;22(1):96-105. doi: 10.4274/tjod.galenos.2025.36926. Turk J Obstet Gynecol. 2025. PMID: 40062715 Free PMC article.
-
Prevention of Pregnancy Loss: Combining Progestogen Treatment and Psychological Support.J Clin Med. 2023 Feb 24;12(5):1827. doi: 10.3390/jcm12051827. J Clin Med. 2023. PMID: 36902614 Free PMC article. Review.
-
The effect of progesterone suppositories on threatened abortion: a randomized clinical trial.J Reprod Infertil. 2014 Jul;15(3):147-51. J Reprod Infertil. 2014. PMID: 25202672 Free PMC article.
-
The Role Of Progestogens In Threatened And Idiopathic Recurrent Miscarriage.Int J Womens Health. 2019 Nov 7;11:589-596. doi: 10.2147/IJWH.S224159. eCollection 2019. Int J Womens Health. 2019. PMID: 31807086 Free PMC article. Review.
-
Efficacy and safety of Gushen Antai Pills combined with dydrogesterone in the treatment of threatened miscarriage: a systematic review and meta-analysis.Front Pharmacol. 2023 Jun 2;14:1138968. doi: 10.3389/fphar.2023.1138968. eCollection 2023. Front Pharmacol. 2023. PMID: 37332346 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical